Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 13/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372288 | 0.93 | CYP3A4 (0.65) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL8142617 | 0.93 | CYP3A4 (0.65) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL3375479 | 0.93 | CYP3A4 (0.65) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL6913229 | 0.92 | CYP3A4 (0.58) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL12464038 | 0.89 | CYP3A4 (0.54) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL12336181 | 0.89 | CYP3A4 (0.53) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL12779428 | 0.89 | CYP3A4 (0.56) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL12779845 | 0.88 | CYP3A4 (0.52) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL6914584 | 0.87 | CYP3A4 (0.51) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL3408415 | 0.86 | CYP3A4 (0.64) | CYP3A4CTSBELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CTSB 630/4885ELANE 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.